2014
DOI: 10.1002/jmv.23876
|View full text |Cite
|
Sign up to set email alerts
|

Interleukin‐28b CC genotype predicts early treatment response and CT/TT genotypes predicts non‐response in patients infected with HCV genotype 3

Abstract: Response to antiviral therapy for hepatitis C virus (HCV) depends upon the genotype and host immune response. IL28b gene mutations have been shown to modulate host antiviral immune response against genotype 1. However, the predictive value of IL28b polymorphism in genotype 3 HCV patients is largely unknown. The association of IL28b polymorphism with virological response was studied in 356 patients with genotype 3 chronic HCV undergoing treatment with peg-interferon and ribavirin and was compared with matched c… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2014
2014
2020
2020

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 11 publications
(6 citation statements)
references
References 35 publications
0
6
0
Order By: Relevance
“…The scenario is different if one considers GT3 HCV separately or uses an adequate sample size. In fact, it has been recently reported from the largest studies that the rs12979860 CC genotype is an independent predictive factor for an SVR also in GT3 HCV patients, whereas no association with an SVR in GT2 HCV infection was observed [40,41]. These data clearly suggest the relevance of sample size in determining the correlation between IL-28B genotype and RVR/SVR, and suggest a rationale for testing IL-28B genotyping also in patients with GT3 HCV.…”
Section: Ifn-λ3 (Il-28b) Ifn-λ4 Ifn-λ2 (Il-28a) Ifn-λ1 (Il-mentioning
confidence: 84%
“…The scenario is different if one considers GT3 HCV separately or uses an adequate sample size. In fact, it has been recently reported from the largest studies that the rs12979860 CC genotype is an independent predictive factor for an SVR also in GT3 HCV patients, whereas no association with an SVR in GT2 HCV infection was observed [40,41]. These data clearly suggest the relevance of sample size in determining the correlation between IL-28B genotype and RVR/SVR, and suggest a rationale for testing IL-28B genotyping also in patients with GT3 HCV.…”
Section: Ifn-λ3 (Il-28b) Ifn-λ4 Ifn-λ2 (Il-28a) Ifn-λ1 (Il-mentioning
confidence: 84%
“…A number of studies have postulated that T-allele of rs12979860 was associated with worst SVR in CHC patients during the IFN treatment, although the mechanisms that da Cunha ECM et al . IL28B and Depression Symptoms in HCV regulate the IL28B genotypes on the success rate of therapy remain unclear [9,19,20,21,22] . In fact, this SNP had been claimed as the key predictor among IL28B SNPs for SVR in HCV infected patients [19] .…”
Section: Discussionmentioning
confidence: 99%
“…IL-28B polymorphisms are associated with SVR and RVR to PEG-IFN/RBV treatment in HCV-1 [ 41 44 ] and HCV-2/3 [ 45 , 46 ]. However, IL-28B genomic-based treatment paradigms for chronic hepatitis C infection need to be demonstrated in clinical trials.…”
Section: Discussionmentioning
confidence: 99%